🔖
Bu Makaleye Atıf Yap
AL-JUDAIBI, B. (2022). Proton pompa inhibitörü ve klopidogrel etkileşimi: Klinik olarak önemli mi?. Turkish Journal of Gastroenterology, Cilt: 22 - Sayı: 6, 649–650. https://ajindex.com/articles/606348
Dergiler / Turkish Journal of Gastroenterology / 2011 / Cilt: 22 - Sayı: 6
Proton pompa inhibitörü ve klopidogrel etkileşimi: Klinik olarak önemli mi?
- Sayfa
- 649–650
- Yayın Tarihi
- 2022-11-05
- DOI
- —
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗Kaynakça (4)
- Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52: 1502-17
- Bliden KP, DiChiara J, Tantry US, et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007; 49: 657-66
- US Food and Drug Administration. US Food and Drug Administration; Nov 18, 2009 [cited 2010 May 20]; Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ 2009/ucm191169.htm
- Bhatt D. A prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Transcatheter Cardiovascular Therapeutics; 2009 [cited 2010 May 20]; Available from: http://assets.cardiosource. com/Bhatt_COGENT.ppt.